Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF induction followed by cetuximab and radiation in locally advanced SCCHN
NCT00721513Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2008
- Primary completion
- Aug 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Wake Forest University Health Sciences. Started Sep 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00721513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00721513.